Research Grade Blosozumab

Catalog No.

DHJ48702

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

SOST, Sclerostin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9BQB4

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

LY2541546, CAS: 1132758-87-2

Clone ID

Blosozumab

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab, PMID: 28547661

Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis, PMID: 25954248

Molecular genetics and targeted therapy of WNT-related human diseases (Review), PMID: 28731148

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density, PMID: 25707611

Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women, PMID: 23996473

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density, PMID: 25196993

Emerging drugs for osteoporosis, PMID: 24995794

Sclerostin and skeletal health, PMID: 25669441

Pharmacometrics and systems pharmacology for metabolic bone diseases, PMID: 30690761

Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis, PMID: 33302631

New insights into treatment of osteoporosis in postmenopausal women, PMID: 26557374

Biological agents in management of osteoporosis, PMID: 25204309

Anti-sclerostin antibodies: utility in treatment of osteoporosis, PMID: 24842796

Future directions for new medical entities in osteoporosis, PMID: 25432357

Sclerostin Inhibition in the Management of Osteoporosis, PMID: 27016922

Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis, PMID: 26082665

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential, PMID: 28974988

Exploiting the WNT Signaling Pathway for Clinical Purposes, PMID: 28432596

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases, PMID: 24688605

[Pharmacology of bone anabolic agents], PMID: 26529924

Clinical utility of anti-sclerostin antibodies, PMID: 28115281

[The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application], PMID: 28635854

Romosozumab: a novel bone anabolic treatment option for osteoporosis?, PMID: 31858345

Latest on Anabolic Agents for Osteoporosis Treatment., PMID:39448133

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion., PMID:37682072

Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis., PMID:36367007

Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis., PMID:35264832

Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review., PMID:34920938

Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis., PMID:33302631

Romosozumab: a novel bone anabolic treatment option for osteoporosis?, PMID:31858345

Pharmacometrics and systems pharmacology for metabolic bone diseases., PMID:30690761

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential., PMID:28974988

Molecular genetics and targeted therapy of WNT-related human diseases (Review)., PMID:28731148

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab., PMID:28547661

Exploiting the WNT Signaling Pathway for Clinical Purposes., PMID:28432596

Clinical utility of anti-sclerostin antibodies., PMID:28115281

Sclerostin Inhibition in the Management of Osteoporosis., PMID:27016922

[The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application]., PMID:28635854

New insights into treatment of osteoporosis in postmenopausal women., PMID:26557374

[Pharmacology of bone anabolic agents]., PMID:26529924

Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis., PMID:26082665

Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis., PMID:25954248

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density., PMID:25707611

Sclerostin and skeletal health., PMID:25669441

Future directions for new medical entities in osteoporosis., PMID:25432357

Biological agents in management of osteoporosis., PMID:25204309

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density., PMID:25196993

Emerging drugs for osteoporosis., PMID:24995794

Anti-sclerostin antibodies: utility in treatment of osteoporosis., PMID:24842796

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases., PMID:24688605

Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women., PMID:23996473

Document Download

Research Grade Blosozumab.pdf